Exchange Traded Concepts LLC Has $884,000 Holdings in Natera, Inc. (NASDAQ:NTRA)

Exchange Traded Concepts LLC lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 53.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,587 shares of the medical research company's stock after selling 6,477 shares during the period. Exchange Traded Concepts LLC's holdings in Natera were worth $884,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of NTRA. Dimensional Fund Advisors LP grew its position in Natera by 35.6% in the second quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company's stock worth $28,680,000 after acquiring an additional 69,523 shares during the period. Bank of Montreal Can grew its holdings in shares of Natera by 58.3% during the 2nd quarter. Bank of Montreal Can now owns 72,293 shares of the medical research company's stock worth $8,068,000 after purchasing an additional 26,615 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Natera by 24.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,257 shares of the medical research company's stock worth $3,926,000 after purchasing an additional 7,132 shares during the last quarter. Mackenzie Financial Corp purchased a new stake in Natera in the 2nd quarter valued at about $317,000. Finally, Creative Planning lifted its position in Natera by 28.3% in the second quarter. Creative Planning now owns 4,929 shares of the medical research company's stock valued at $534,000 after buying an additional 1,087 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 5,201 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total value of $862,689.87. Following the completion of the sale, the insider now directly owns 135,483 shares of the company's stock, valued at approximately $22,472,565.21. This represents a 3.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 13,685 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total value of $2,269,930.95. Following the completion of the transaction, the chief executive officer now owns 253,944 shares in the company, valued at $42,121,691.28. This trade represents a 5.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 263,894 shares of company stock worth $43,801,978. Corporate insiders own 7.60% of the company's stock.

Analyst Ratings Changes

NTRA has been the subject of a number of recent analyst reports. Canaccord Genuity Group lifted their price target on shares of Natera from $165.00 to $180.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. StockNews.com lowered Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. Craig Hallum upped their price target on Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. The Goldman Sachs Group boosted their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $165.88.

Natera Stock Up 0.4 %

NTRA traded up $0.65 on Friday, reaching $176.92. The company's stock had a trading volume of 1,237,479 shares, compared to its average volume of 1,269,035. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a fifty-two week low of $64.74 and a fifty-two week high of $183.00. The stock has a 50 day moving average of $166.89 and a two-hundred day moving average of $138.31. The company has a market capitalization of $23.36 billion, a price-to-earnings ratio of -100.52 and a beta of 1.65.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same period last year, the firm posted ($0.95) EPS. The company's revenue was up 63.9% on a year-over-year basis. As a group, analysts forecast that Natera, Inc. will post -1.56 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.